Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Notes Payables (2017 - 2019)

Anaptysbio filings provide 3 years of Notes Payables readings, the most recent being $1.4 million for Q4 2019.

  • For the quarter ending Q4 2019, Notes Payables fell 81.85% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Dec 2019, down 81.85%, and an annual FY2019 reading of $1.4 million, down 81.85% over the prior year.
  • Notes Payables hit $1.4 million in Q4 2019 for Anaptysbio, down from $3.1 million in the prior quarter.
  • The five-year high for Notes Payables was $7.6 million in Q4 2018, with the low at $1.2 million in Q1 2017.
  • Median Notes Payables over the past 3 years was $5.7 million (2017), compared with a mean of $5.2 million.
  • The sharpest move saw Notes Payables skyrocketed 500.0% in 2018, then tumbled 81.85% in 2019.
  • Year by year, Notes Payables stood at $6.9 million in 2017, then grew by 10.17% to $7.6 million in 2018, then tumbled by 81.85% to $1.4 million in 2019.
  • According to Business Quant data, Notes Payables over the past three periods came in at $1.4 million, $3.1 million, and $4.8 million for Q4 2019, Q3 2019, and Q2 2019 respectively.